Future research should investigate the interplay between UBAP2L-dependent SG functions and broader metabolic or immune pathways in ccRCC, as well as validate OGT inhibition in preclinical and clinical settings. Here, UBAP2L is linked to nonpapillary renal cell carcinoma.